12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CCX832: Phase I started

ChemoCentryx began a placebo-controlled, dose-escalation, Swiss Phase I trial to evaluate CCX832 in healthy volunteers. The trial start triggers a $10 million milestone payment from

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >